Retension grants Robert Wong 25,000 stock options

The award was made under Retension Pharmaceuticals’ 2026 Equity Incentive Plan.

Available on EDGAR 11/04/2026 - 04:32 PM EST Accepted by SEC EDGAR 11/04/2026 - 04:31 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Retension Pharmaceuticals, Inc. reported that Robert Wong, its VP, Chief Accounting Officer, was granted 25,000 stock options on November 2, 2026. The options have an exercise price of $11.30 per share and expire November 2, 2036. Twenty-five percent vests on the first anniversary of the grant; the remaining options vest in 36 equal monthly increments thereafter, subject to Robert Wong’s continued service on each vesting date.

Insider Trade Summary

Grant/Award: 25,000 shares

Grant/Award 1 txn

Insider Wong Robert

Role VP, Chief Accounting Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy) F1	25,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 25,000 contracts (Direct)

Footnotes (1)

1. F1. Option award granted pursuant to the Issuer's 2026 Equity Incentive Plan. Twenty-five percent of the stock option vests on the first anniversary of the date of grant, with the remaining stock options vesting in 36 equal monthly increments thereafter, subject to the Reporting Person's continued service to the Issuer on each vesting date.

Key Figures

Stock options awarded: 25,000 stock options Exercise price: $11.30 per share First vesting tranche: 25% +2 more

5 metrics

Stock options awarded 25,000 stock options Granted to Robert Wong on November 2, 2026

Exercise price $11.30 per share Stock options granted November 2, 2026

First vesting tranche 25% Vests on the first anniversary of the grant, subject to continued service

Remaining vesting schedule 36 equal monthly increments After the first anniversary of the grant, subject to continued service

Expiration date November 2, 2036 Stock options granted to Robert Wong

Key Terms

vesting, stock option, 2026 Equity Incentive Plan

3 terms

vesting technical

"stock options vesting in 36 equal monthly increments"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

stock option financial

"Twenty-five percent of the stock option vests"

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

2026 Equity Incentive Plan financial

"granted pursuant to the Issuer's 2026 Equity Incentive Plan"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many stock options did RTSN’s chief accounting officer receive?

Robert Wong, Retension Pharmaceuticals’ VP, Chief Accounting Officer, was granted 25,000 stock options on November 2, 2026, with an exercise price of $11.30 per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wong Robert

(Last) (First) (Middle)

1104 WEST BROAD STREET

SUITE 1029

(Street)

FALLS CHURCH VIRGINIA 22046

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Retension Pharmaceuticals, Inc. [ RTSN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	VP, Chief Accounting Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
11/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)(1)	$11.3	11/02/2026		A		25,000		(1)	11/02/2036	Common Stock	25,000	$0	25,000	D

Explanation of Responses:

1. Option award granted pursuant to the Issuer's 2026 Equity Incentive Plan. Twenty-five percent of the stock option vests on the first anniversary of the date of grant, with the remaining stock options vesting in 36 equal monthly increments thereafter, subject to the Reporting Person's continued service to the Issuer on each vesting date.

	/s/ Alex Schwartz, Attorney-in-fact	11/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)